235 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 6 of 6
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Meyer Kattan, MD
Status: Currently Recruiting
We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Erika Berman-Rosenzweig, MD
Status: Closed
This is a clinical research study designed to determine the safety and effectiveness of the TIVUS system, an investigational device used in the treatment of PAH. The TIVUS System is intended to treat patients with pulmonary artery hypertension by injuring the sympathetic nerves surrounding the pulmonary vasculature (denervation) using ultrasonic energy. The…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Joyce Yu, MD
Status: Closed
This study is designed to examine the efficacy and safety profile of dupilumab over one year in a population of asthmatic children in need for an additional treatment to their current maintenance management. Patients are randomized to either dupilumab or matching placebo administered standard care for a maximum treatment duration of 52 weeks. The…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Joyce Yu, MD
Status: Closed
The purpose of this global study is to provide evidence of the efficacy and safety of 210 mg dose of tezepelumab administered every 4 weeks subcutaneously in adults and adolescents (12 years of age and older) with a history of asthma exacerbations and severe uncontrolled asthma receiving medium or high dose inhaled corticosteroids plus at least one…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: David Lederer, MD
Status: Closed
The purpose of this study is to study the effects of a new study drug known as Riociguat in people diagnosed with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Patients will be in the study for approximately 26 weeks in which they will take the pill Riogciguat three times a day.
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Elana Bernstein, MD
Status: Closed
This study involves two infusions of either rituximab or placebo, two right heart catheterizations (6 months apart), and a variety of other clinical study procedures and exams.